Hope, quality of life, and benefit from treatment in women having chemotherapy for platinum-resistant/refractory recurrent ovarian cancer: The gynecologic cancer intergroup symptom benefit study

Oncologist

Volumn 18, Issue 11, 2013, Pages 1221-1228

  Sjoquist, Katrin M ^a   Friedlander, Michael L ^a   O'Connell, Rachel L ^a   Voysey, Merryn ^a   King, Madeleine T ^a   Stockler, Martin R ^a   Oza, Amit M ^b   Gillies, Kim ^a   Martyn, Julie K ^a   Butow, Phyllis N ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Chemotherapy; Hope; Recurrent ovarian cancer; Symptom benefit; Symptoms

Indexed keywords

ADULT; AGED; ANXIETY; ARTICLE; CANCER SURVIVAL; DEPRESSION; FEMALE; FOLLOW UP; HOPE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PSYCHOLOGICAL WELL BEING; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; TREATMENT OUTCOME;

CHEMOTHERAPY; HOPE; RECURRENT OVARIAN CANCER; SYMPTOM BENEFIT; SYMPTOMS;

ADULT; AGED; AGED, 80 AND OVER; ANXIETY; DEPRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; HOPE; HUMANS; LONGITUDINAL STUDIES; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PROGNOSIS; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 84887474742     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0175     Document Type: Article

References (45)

1. Colombo N, Van Gorp T, Parma G et al. Ovarian cancer. Crit Rev Oncol Hematol 2006;60:159-179.
2. Herzog TJ, Pothuri B. Ovarian cancer:Afocus on management of recurrent disease. Nat Clin Pract Oncol 2006;3:604-611.
3. Rustin G, Tuxen M. Use ofCA125 in follow-up of ovarian cancer. Lancet 1996;348:191-192.
4. Blackledge G, Lawton F, Redman C et al. Response of patients in phase II studies of chemotherapy in ovarian cancer: Implications for patient treatment and the design of phase II trials. Br J Cancer 1989;59:650-653.
5. Markman M, Rothman R, Hakes T et al. Secondline platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991;9:389-393.
6. Gordon AN, Fleagle JT, Guthrie D et al. Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001;19:3312-3322.
7. Doyle C, Crump M, Pintilie M., et al. Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer. J Clin Oncol 2001;19:1266-1274.
8. Weeks JC, Catalano PJ, Cronin A et al. Patients' expectations about effects of chemotherapy for advanced cancer. N Engl J Med 2012;367: 1616-1625.
9. von Gruenigen VE, Daly BJ. Treating ovarian cancer patients at the end of life: When should we stop? Gynecol Oncol 2005;99:255-256.
10. von Gruenigen VE, Daly BJ. Futility: Clinical decisions at the end-of-life in women with ovarian cancer. Gynecol Oncol 2005;97:638-644.
11. Bowes DE, Tamlyn D, Butler LJ. Women living with ovarian cancer: Dealing with an early death. Health Care Women Int 2002;23:135-148.
12. Post-White JJ. Howhope affects healing. Creat Nurs 2003;9:10-11.
13. Reb AM. Transforming the death sentence: Elements of hope in women with advanced ovarian cancer. Oncol Nurs Forum 2007;34:E70-81.
14. Ballard A, Green T, McCaa A et al. A comparison of the level of hope in patients with newly diagnosed and recurrent cancer. Oncol Nurs Forum 1997;24:899-904.
15. Chi GC. The role of hope in patients with cancer. Oncol Nurs Forum 2007;34:415-424.
16. Herth KA, Cutcliffe JR. The concept of hope in nursing 3:Hopeandpalliative care nursing. Br J Nurs 2002;11:977-983.
17. Rustoen T. Hopeandquality of life,twocentral issues for cancer patients: A theoretical analysis. Cancer Nurs 1995;18:355-361.
18. Eliott J, Olver I. The discursive properties of "hope": A qualitative analysis of cancer patients' speech. Qual Health Res 2002;12:173-193.
19. Herth K. Abbreviated instrument to measure hope: Development and psychometric evaluation. J Adv Nurs 1992;17:1251-1259.
20. Dufault K, BC M. Symposium on compassionate care and the dying experience: Hope-its spheres and dimensions. Nurs Clin North Am 1985; 20:379-391.
21. Daneault S, Dion D, Sicotte C et al. Hope and noncurative chemotherapies: Which affects the other? J Clin Oncol 2010;28:2310-2313.
22. Ferrell B, Cullinane CA, Ervine K et al. Perspectives on the impact of ovarian cancer: Women's views of quality of life. Oncol Nurs Forum 2005;32: 1143-1149.
23. McCorkle R, Pasacreta J, Tang ST. The silent killer: Psychological issues in ovarian cancer. Holist Nurs Pract 2003;17:300-308.
24. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67:361-370.
25. Bjelland I, Dahl AA, Haug TT et al. Thevalidity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res 2002;52: 69-77.
26. Basen-Engquist K, Bodurka-Bevers D, Fitzgerald MA et al. Reliabilityandvalidity of the Functional Assessment of Cancer Therapy-Ovarian. J Clin Oncol 2001;19:1809-1817.
27. Cohen J. A power primer. Psychol Bull 1992; 112:155-159.
28. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: The remarkable universality of half a standard deviation. Med Care 2003;41:582-592.
29. Peduzzi P, Concato J, Kemper E et al. A simulation study of thenumberof events per variable in logistic regression analysis. J Clin Epidemiol 1996;49: 1373-1379.
30. Friedlander ML, Voysey M, King M et al. Symptom burden in patients with platinum resistant/refractory ovarian cancer-final results of stage 1 of GCIG symptom benefit study (SBS). Int J Gyn Ca 2011;21(suppl 3, 12):S1-S1372.
31. Robinson T, Alexander S, Hays M., et al. Patient-oncologistcommunicationinadvancedcancer: Predictors of patient perception of prognosis. Supportive Care Cancer 2008;16:1049-1057.
32. Smith TJ, Dow LA, Virago E et al. Giving honest information to patients with advanced cancer maintains hope. Oncology 2010;24:521-525.
33. Kiely BE, Tattersall MHN, Stockler MR. Certain death in uncertain time: Informing hope by quantifying a best case scenario. J Clin Oncol 2010;28: 2802-2804.
34. Kiely BE, McCaughan G, Christodoulou S et al. Using scenarios to explain life expectancy in advancedcancer: Attitudes of people withacancer experience. Supportive Care Cancer 2013;21:369-376.
35. Grunfeld EA, Ramirez AJ, Maher EJ et al. Chemotherapy for advanced breast cancer: What influences oncologists' decision-making? Br J Cancer 2001;84:1172-1178.
36. Matsuyama R, Reddy S, Smith TJ. Why do patients choose chemotherapy near the end of life? A review of the perspective of those facing death from cancer. J Clin Oncol 2006;24:3490-3496.
37. Weeks J, Cook E, O'Day S et al. Relationship betweencancer patients' predictions of prognosisand their treatment preferences. JAMA 1998;27:1709-1714.
38. Schneiderman LJ. The perils of hope. Camb Q Healthc Ethics 2005;14 235-239.
39. Grandinetti D. "Ethical hope"-a lifeline for sick patients. Med Econ 1999; 76: 118.
40. Wright AA, Zhang B, Ray A et al. Associations between end-of-life discussions, patient mental health, medical care near death, and caregiver bereavement adjustment. JAMA 2008;300:1665-1673.
41. Picherak T. The 1999 Schering Lecture. Cancer: The long and winding road. Can Oncol Nurs J 2000; 10:50-55.
42. Links M, Kramer J. Breakingbadnews:Realistic versus unrealistic hopes. Supportive Care Cancer 1994;2:91-93.
43. Mileshkin LR, Antippa P, Schofield P. Stories of the music of hope. Med J Aust 2012;196 276-277.
44. Clayton JM, Butow PN, Arnold RM et al. Fostering coping and nurturing hope when discussing the future with terminally ill cancer patients and their caregivers. Cancer 2005;103:1965-1975.
45. Gum A, Snyder CR. Coping with terminal illness: The role of hopeful thinking. J Palliat Med 2002;5:883-894.